Intuitive Surgical Inc

Intuitive Surgical designs, manufactures, and services the da Vinci Surgical System, a robotic platform for minimally invasive surgery. The company generates revenue through three streams: capital equipment sales of da Vinci systems to hospitals, recurring revenue from instruments and accessories used in each procedure, and service contracts. The business model creates a razor-and-blade dynamic, with procedure volume driving high-margin consumable sales after the initial system placement.

Intuitive trades at premium P/E multiples reflecting its market leadership in robotic surgery and strong procedural growth trends. The company demonstrates pricing power through consumable sales and benefits from long product replacement cycles. Key risks include competition from Johnson & Johnson and Medtronic entering robotic surgery, potential pricing pressure from hospital consolidation, regulatory hurdles for new procedures, and dependence on surgeon training and adoption. Margins have remained consistently high as procedure volume scales.

Johnson & Johnson acquired Auris Health and Verb Surgical to develop competing robotic platforms, though still gaining market traction. Medtronic launched the Hugo surgical robot targeting international markets and specific procedures. Stryker offers the Mako system for orthopedic surgery. CMR Surgical (UK-based) markets the Versius robot globally. Asensus Surgical competes in select procedures, though with far smaller installed base than da Vinci's thousands of systems worldwide.

Intuitive built powerful network effects through surgeon training and procedural familiarity with da Vinci systems. Hospitals invest heavily in training surgical teams, creating switching costs that protect market share even as competitors emerge. The installed base of over 8,000 systems worldwide generates predictable recurring revenue from instruments and service contracts. This razor-and-blade model delivers expanding margins as procedure volumes grow, while competitors must overcome both technical and adoption hurdles.

ISRG last closed at $470.18, down 0.37% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $425.00 and a high of $603.88. The current price represents 25% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 42 analysts covering ISRG, the consensus rating is Buy — 29 rate it a buy, 12 hold, and 1 sell. The average price target sits at $219.77, implying 53% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Intuitive Surgical Inc generated $9.91B in revenue during fiscal year 2026, with $2.81B reaching the bottom line as net income. The net profit margin of 28.4% is strong by most industry standards.

ISRG trades at a P/E ratio of 59.80 on trailing earnings of $7.88 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -18.63% (3M), +6.59% (6M), -9.55% (1Y), -16.34% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether ISRG is outperforming or lagging the broader market.